Ei­sai sub­sidiary nabs Japan rights for schiz­o­phre­nia drug; No­vavax's $50M mile­stone

Plus, news about Can­del, In­ovio and Re­meGene:

Ei­sai li­cens­es Newron Phar­ma­ceu­ti­cals’ eve­namide: Ei­sai’s sub­sidiary EA Phar­ma will pay up to €117 mil­lion ($123 mil­lion) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER